Pasquale Lombardi

机构：Università Cattolica del Sacro Cuore, Hammersmith Hospital, Agostino Gemelli University Polyclinic, Imperial College London · ORCID：0000-0001-6262-2161

发表论文 115 篇 · 总被引 1457 次 · h-index 20

代表论文

• Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study (2025 · JHEP Reports · 被引 12)
• Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma (2025 · JAMA Oncology · 被引 9)
• The financial toll of cancer: uncovering the links between financial toxicity and symptom burden (2025 · The Oncologist · 被引 9)
• Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023) (2025 · European Journal of Cancer · 被引 7)
• Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab (2025 · Journal for ImmunoTherapy of Cancer · 被引 3)
• A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma (2026 · Journal of Hepatology · 被引 2)